Prexasertib Mesylate is a novel CHK1 inhibitor under investigation as a chemopotentiating agent. It causes double-stranded DNA breakage while simultaneously removing the protection of the DNA damage checkpoints. Prexasertib Mesylate is representative of a novel class of drugs for the treatment of cancer and tumor growth inhibition.
